Boston Scientific Corp
BSX91.924USD
-0.656-0.71%
Market hours （ET）Quotes delayed by 15 min
136.26BMarket Cap
48.69P/E TTM
More Details of Boston Scientific Corp Company
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Boston Scientific Corp Info
Ticker SymbolBSX
Company nameBoston Scientific Corp
IPO dateMay 19, 1992
CEOMahoney (Michael F)
Number of employees53000
Security typeOrdinary Share
Fiscal year-endMay 19
Address300 Boston Scientific Way
CityMARLBOROUGH
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code01752-1234
Phone15086834000
Websitehttps://www.bostonscientific.com/en-US/Home.html
Ticker SymbolBSX
IPO dateMay 19, 1992
CEOMahoney (Michael F)
Company Executives of Boston Scientific Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
41.58K
+5.27%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.29K
+1.62%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
24.13K
-34.82%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
5.63K
+58.67%
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.08K
-58.23%
Mr. Arthur Crosswell Butcher
Mr. Arthur Crosswell Butcher
Executive Vice President, Group President, MedSurg and Asia Pacific
Executive Vice President, Group President, MedSurg and Asia Pacific
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
41.58K
+5.27%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.29K
+1.62%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
24.13K
-34.82%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Electrophysiology
840.00M
16.60%
Endoscopy
737.00M
14.56%
Interventional Cardiology Therapies
731.00M
14.44%
Peripheral Interventions
698.00M
13.79%
Urology
676.00M
13.36%
Other
1.38B
27.25%
By RegionUSD
Name
Revenue
Proportion
United States
3.22B
63.70%
EMEA (Europe, Middle East and Africa)
878.00M
17.35%
Asia Pacific
790.00M
15.61%
Latin America and Canada
169.00M
3.34%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Electrophysiology
840.00M
16.60%
Endoscopy
737.00M
14.56%
Interventional Cardiology Therapies
731.00M
14.44%
Peripheral Interventions
698.00M
13.79%
Urology
676.00M
13.36%
Other
1.38B
27.25%
Shareholding Stats
Updated: Sat, Nov 8
Updated: Sat, Nov 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.28%
Fidelity Management & Research Company LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.37%
State Street Investment Management (US)
4.38%
PRIMECAP Management Company
2.23%
Other
72.63%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.28%
Fidelity Management & Research Company LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.37%
State Street Investment Management (US)
4.38%
PRIMECAP Management Company
2.23%
Other
72.63%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.76%
Investment Advisor/Hedge Fund
29.08%
Hedge Fund
4.91%
Pension Fund
2.94%
Research Firm
2.73%
Bank and Trust
1.89%
Sovereign Wealth Fund
1.58%
Family Office
0.23%
Private Equity
0.18%
Other
5.69%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
2858
1.40B
94.34%
-402.85K
2025Q3
2905
1.40B
94.56%
+9.92M
2025Q2
2818
1.39B
94.08%
+7.87M
2025Q1
2724
1.38B
93.98%
-8.23M
2024Q4
2559
1.38B
93.68%
+12.79M
2024Q3
2401
1.36B
94.13%
-3.01M
2024Q2
2325
1.37B
94.20%
+2.64M
2024Q1
2212
1.37B
95.15%
-32.63M
2023Q4
2153
1.38B
96.34%
-8.17M
2023Q3
2083
1.39B
95.41%
+17.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
136.47M
9.21%
+2.53M
+1.89%
Jun 30, 2025
Fidelity Management & Research Company LLC
99.47M
6.71%
-17.98M
-15.31%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
78.19M
5.28%
+380.40K
+0.49%
Jun 30, 2025
State Street Investment Management (US)
65.19M
4.4%
+713.38K
+1.11%
Jun 30, 2025
PRIMECAP Management Company
34.66M
2.34%
-1.83M
-5.03%
Jun 30, 2025
Geode Capital Management, L.L.C.
32.42M
2.19%
+622.60K
+1.96%
Jun 30, 2025
Capital World Investors
28.52M
1.93%
-33.95K
-0.12%
Jun 30, 2025
Managed Account Advisors LLC
22.05M
1.49%
+765.61K
+3.60%
Jun 30, 2025
The Bollard Group, LLC
20.08M
1.36%
-411.38K
-2.01%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
19.46M
1.31%
-275.11K
-1.39%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Dec 1
Updated: Mon, Dec 1
Name
Proportion
iShares U.S. Medical Devices ETF
12.15%
Goldman Sachs Future Health Care Equity ETF
8.33%
Invesco Dorsey Wright Healthcare Momentum ETF
3.87%
Tema Heart & Health ETF
3.66%
First Trust Bloomberg R&D Leaders ETF
3.14%
Parnassus Core Select ETF
3.1%
WisdomTree US AI Enhanced Value Fund
3.1%
Health Care Select Sector SPDR Fund
3.06%
Global X Aging Population ETF
2.99%
Proshares Ultra Health Care
2.95%
View more
iShares U.S. Medical Devices ETF
Proportion12.15%
Goldman Sachs Future Health Care Equity ETF
Proportion8.33%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.87%
Tema Heart & Health ETF
Proportion3.66%
First Trust Bloomberg R&D Leaders ETF
Proportion3.14%
Parnassus Core Select ETF
Proportion3.1%
WisdomTree US AI Enhanced Value Fund
Proportion3.1%
Health Care Select Sector SPDR Fund
Proportion3.06%
Global X Aging Population ETF
Proportion2.99%
Proshares Ultra Health Care
Proportion2.95%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Boston Scientific Corp?
The top five shareholders of Boston Scientific Corp are:
The Vanguard Group, Inc. holds 136.47M shares, accounting for 9.21% of the total shares.
Fidelity Management & Research Company LLC holds 99.47M shares, accounting for 6.71% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 78.19M shares, accounting for 5.28% of the total shares.
State Street Investment Management (US) holds 65.19M shares, accounting for 4.40% of the total shares.
PRIMECAP Management Company holds 34.66M shares, accounting for 2.34% of the total shares.
The Vanguard Group, Inc. holds 136.47M shares, accounting for 9.21% of the total shares.
Fidelity Management & Research Company LLC holds 99.47M shares, accounting for 6.71% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 78.19M shares, accounting for 5.28% of the total shares.
State Street Investment Management (US) holds 65.19M shares, accounting for 4.40% of the total shares.
PRIMECAP Management Company holds 34.66M shares, accounting for 2.34% of the total shares.
What are the top three shareholder types of Boston Scientific Corp?
The top three shareholder types of Boston Scientific Corp are:
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Boston Scientific Corp (BSX)?
As of 2025Q4, 2858 institutions hold shares of Boston Scientific Corp, with a combined market value of approximately 1.40B, accounting for 94.34% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.23%.
What is the biggest source of revenue for Boston Scientific Corp?
In FY2025Q2, the Electrophysiology business generated the highest revenue for Boston Scientific Corp, amounting to 840.00M and accounting for 16.60% of total revenue.
